Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04055818 · ClinicalTrials.gov registry record · Phase 1
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
A Phase 1 study of Sickle Cell Disease, sponsored by EpiDestiny.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04055818 is a Phase 1 study of Sickle Cell Disease that is actively recruiting participants, run by EpiDestiny. The registered enrollment target is 20 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04055818, a Phase 1 study of Sickle Cell Disease, is actively recruiting participants, sponsored by EpiDestiny.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Conditions Studied
Interventions
- DRUG Nicotinamide
Study Locations (1)
Illinois
- University of Illinois at Chicago College of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-01-24 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04055818
The ClinicalTrials.gov registry entry for NCT04055818 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The listed sponsor is EpiDestiny, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Nicotinamide is the first listed.
NCT04055818 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04055818 about?
NCT04055818 is a clinical study titled "A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease". A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
What is the current status of trial NCT04055818?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-01-24. Estimated completion is 2027-04-30.
What conditions does trial NCT04055818 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT04055818?
The interventions under investigation include: Nicotinamide (DRUG).
Who is sponsoring clinical trial NCT04055818?
This trial is sponsored by EpiDestiny, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04055818 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.